Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00877045
• Other study ID #: SCRI OUTCOMES 01
• Status: Completed
• Phase: N/A
• First received: April 3, 2009
• Last updated: August 3, 2010
• Start date: January 2008
• Est. completion date: February 2009

Study information

• Verified date: August 2010
• Source: SCRI Development Innovations, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: February 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors

Locations

Country	Name	City	State
United States	Georgia Cancer Specialists	Atlanta	Georgia
United States	Chattanooga Oncology Hematology Associates	Chattanooga	Tennessee
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Tennessee Oncology, PLLC	Nashville	Tennessee
United States	Virginia Cancer Institute	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
SCRI Development Innovations, LLC	Pfizer

Country where clinical trial is conducted

United States,